Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Merck & Co.'s Keytruda gets positive opinion from EMA's CHMP

Dec. 19, 2016

ElsaLys Biotech acquires rights to anti-CD115 antibody from Transgene

Dec. 19, 2016

Dana-Farber studies DPX-E7 for incurable HPV 16-related cancers

Dec. 19, 2016

Takara Bio and Otsuka sign exclusive license agreement for the oncolytic virus HF10 in Japan

Dec. 16, 2016

Amgen describes BiTE antibody targeting EGFR, CD3

Dec. 16, 2016

Mersana begins first-in-human study of XMT-1522 in breast cancer and HER2-expressing cancers

Dec. 16, 2016

Argos Therapeutics and Personalis enter research agreement

Dec. 16, 2016

Polatuzumab vedotin given U.S. orphan drug designation

Dec. 15, 2016

argenx initiates phase I/II study of ARGX-110 with azacitidine in newly diagnosed AML

Dec. 15, 2016

Medicenna Biopharma begins phase II study of MDNA-55

Dec. 15, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...